Literature DB >> 8732732

Cystic fibrosis in adults. From researcher to practitioner.

G P Marelich1, C E Cross.   

Abstract

The Cystic Fibrosis Foundation currently tracks about 20,000 Americans with cystic fibrosis, an autosomal recessive genetic disease that leads to multisystem complications. With the institution of better therapeutic regimens over the past 2 decades, more patients with this disease are surviving to adulthood. Within the past decade, both clinical and basic science research in the field of cystic fibrosis has progressed at a rapid rate. The intent of this review is to introduce readers to the molecular, cellular, and systemic disorders of this disease. We discuss treatment strategies involving antibiotics, nutrition, immune-response mediators, chest physiotherapy, and sputum-active agents with respect to the airway dysfunction of cystic fibrosis. Other common complications, recent developments, transplantation, and gene therapy are also reviewed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8732732      PMCID: PMC1303506     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  117 in total

1.  Identification of the cystic fibrosis gene: genetic analysis.

Authors:  B Kerem; J M Rommens; J A Buchanan; D Markiewicz; T K Cox; A Chakravarti; M Buchwald; L C Tsui
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

2.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.

Authors:  J R Riordan; J M Rommens; B Kerem; N Alon; R Rozmahel; Z Grzelczak; J Zielenski; S Lok; N Plavsic; J L Chou
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

3.  Mutations in CFTR associated with mild-disease-form Cl- channels with altered pore properties.

Authors:  D N Sheppard; D P Rich; L S Ostedgaard; R J Gregory; A E Smith; M J Welsh
Journal:  Nature       Date:  1993-03-11       Impact factor: 49.962

4.  An approach for treating the hepatobiliary disease of cystic fibrosis by somatic gene transfer.

Authors:  Y Yang; S E Raper; J A Cohn; J F Engelhardt; J M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

5.  Carotenoid levels in normal children and in children with cystic fibrosis.

Authors:  D N Homnick; J H Cox; M J DeLoof; T V Ringer
Journal:  J Pediatr       Date:  1993-05       Impact factor: 4.406

6.  Efficacy of aerosolized tobramycin in patients with cystic fibrosis.

Authors:  B W Ramsey; H L Dorkin; J D Eisenberg; R L Gibson; I R Harwood; R M Kravitz; D V Schidlow; R W Wilmott; S J Astley; M A McBurnie
Journal:  N Engl J Med       Date:  1993-06-17       Impact factor: 91.245

7.  Treatment and prognosis of nasal polyps in cystic fibrosis.

Authors:  R C Stern; T F Boat; R E Wood; L W Matthews; C F Doershuk
Journal:  Am J Dis Child       Date:  1982-12

8.  Family correlates of a 10-year pulmonary health trend in cystic fibrosis.

Authors:  J M Patterson; J Budd; D Goetz; W J Warwick
Journal:  Pediatrics       Date:  1993-02       Impact factor: 7.124

9.  Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis.

Authors:  M Knowles; J Gatzy; R Boucher
Journal:  N Engl J Med       Date:  1981-12-17       Impact factor: 91.245

Review 10.  Optimisation of antibiotic therapy in cystic fibrosis patients. Pharmacokinetic considerations.

Authors:  C A Lindsay; J A Bosso
Journal:  Clin Pharmacokinet       Date:  1993-06       Impact factor: 6.447

View more
  2 in total

Review 1.  Cystic fibrosis therapy--where we are and how we got there.

Authors:  D C Gruenert
Journal:  West J Med       Date:  1996-04

2.  Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa.

Authors:  Hayssam Khalil; Tao Chen; Renée Riffon; Rutao Wang; Zhao Wang
Journal:  Antimicrob Agents Chemother       Date:  2008-02-19       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.